13 research outputs found
Hospital Pneumonia
Prema smjernicama AmeriÄkoga torakalnog druÅ”tva (ATS) i AmeriÄkog druÅ”tva za zarazne bolesti (IDSA) iz 2005. godine, razlikujemo tri tipa bolniÄkih pneumonija: bolniÄka pneumonija u užem smislu (HAP), pneumonija povezana s respiratorom (VAP) i pneumonija povezana sa zdravstvenom skrbi (HCAP). HAP nosi najveÄu smrtnost meÄu bolniÄkim infekcijama. Rizik od nastanka pneumonije poveÄava se boravkom u jedinicama intenzivnog lijeÄenja. Infekcija nastaje mikroaspiracijom bakterija iz koloniziranog orofaringealnog trakta i može biti polimikrobna te multirezistentna na lijekove (MDR). MDR je rezistencija bakterije na dva ili viÅ”e antibiotika koji se uobiÄajeno rabe u njezinu lijeÄenju. Infekcija MDR-mikroorganizmima oÄekuje se u bolesnika s odreÄenim Äimbenicima rizika: nedavna upotreba antibiotika, nedavni ili produljeni boravak u bolnici, komorbiditet, kritiÄno stanje bolesnika te izloženost lokalnoj mikrobioloÅ”koj flori. Osim kliniÄkih parametara (naglo nastala vruÄica, purulentna traheobronhalna sekrecija, respiratorno uruÅ”avanje) za dijagnozu HAP-a, VAP-a i HCAP-a potrebno je pouzdano mikrobioloÅ”ko uzorkovanje s analizom kulture uz radioloÅ”ki nalaz novog ili progredirajuÄeg infiltrata na pluÄima. S obzirom na visok mortalitet, lijeÄenje suspektnog HAP-a, VAP-a i HCAP-a ne smije se odgaÄati te empirijski treba primijeniti antibiotik Å”irokog spektra. Ako su odsutni Äimbenici rizika od MDR-infekcije, empirijski se koristimo monoterapijom (beta-laktamima ili fluorokinolonima). Pri sumnji na infekciju MDR-uzroÄnikom izbor je empirijskog lijeÄenja kombinacija lijekova. āPrekrajanjemā poÄetno Å”irokog antibiotskog lijeÄenja prema nalazu testa osjetljivosti (deeskalacija) te kraÄom primjenom antibiotika smanjuje se rizik od nove multirezistencije, toksiÄnosti kombiniranog lijeÄenja i bolniÄke smrtnosti.Three types of hospital pneumonia are recognised by the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines: Hospital-acquired pneumonia (HAP), Ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP). Among all the hospital-acquired infections HAP is responsible for highest mortality rate. The stay in intensive care units increases the risk of pneumonia. Infection develops through microaspiration of bacteria from colonized oropharyngeal tract and may be polymicrobial and caused by multidrug resistant (MDR) pathogens. MDR is defined as resistance of bacteria to two or more antibiotics ordinarily used to treat this microorganism. MDR infection is expected in patients with certain risk factors: recent antibiotic use, recent or prolonged hospital stay, comorbidity, critical illness and exposure to local microbial flora. Besides clinical features (sudden onset fever, purulent tracheobronchial secretions, respiratory deterioration), the diagnosis of HAP, VAP and HCAP is made upon reliable microbiologic sampling and culture analysis in relation to the chest radiograph findings of new or progressive infiltrate. Considering a high mortality rate, the treatment of suspected HAP, VAP and HCAP should not be delayed and empiric broad spectrum antibiotic should be instituted. Empiric antibiotic monotherapy (beta-lactams or fluoroquinolones) is used in the absence of known risk factors for MDR infection. When MDR infection is suspected, empiric combination of drugs is the choice. Tailoring the broad spectrum therapy after susceptibility tests (de-escalation) and shortening the therapy duration reduces the risk of additional drug-resistance, toxicity of combination therapy and in-hospital mortality
Harmonic Structure of Tracheal Biometrics
According to existing research, in 20% of patients the required tracheal size (diameter and length) could not be measured automatically (using software solution). In this paper, we use Zederbauer\u27s harmonic circle to define the relationship between a person\u27s body height and the diameter and length of their trachea. We then explore differences by gender. The results show that there is a highly significant correlation between measured data and values obtained by harmonic analysis. The final goal is to obtain the mathematical interpretation of the relationship of the tracheal size to the height of man, in order to further apply such sizes in the creation of 3D models that could finally be printed on appropriate 3D printers and with the suitable material
Hospital Pneumonia
Prema smjernicama AmeriÄkoga torakalnog druÅ”tva (ATS) i AmeriÄkog druÅ”tva za zarazne bolesti (IDSA) iz 2005. godine, razlikujemo tri tipa bolniÄkih pneumonija: bolniÄka pneumonija u užem smislu (HAP), pneumonija povezana s respiratorom (VAP) i pneumonija povezana sa zdravstvenom skrbi (HCAP). HAP nosi najveÄu smrtnost meÄu bolniÄkim infekcijama. Rizik od nastanka pneumonije poveÄava se boravkom u jedinicama intenzivnog lijeÄenja. Infekcija nastaje mikroaspiracijom bakterija iz koloniziranog orofaringealnog trakta i može biti polimikrobna te multirezistentna na lijekove (MDR). MDR je rezistencija bakterije na dva ili viÅ”e antibiotika koji se uobiÄajeno rabe u njezinu lijeÄenju. Infekcija MDR-mikroorganizmima oÄekuje se u bolesnika s odreÄenim Äimbenicima rizika: nedavna upotreba antibiotika, nedavni ili produljeni boravak u bolnici, komorbiditet, kritiÄno stanje bolesnika te izloženost lokalnoj mikrobioloÅ”koj flori. Osim kliniÄkih parametara (naglo nastala vruÄica, purulentna traheobronhalna sekrecija, respiratorno uruÅ”avanje) za dijagnozu HAP-a, VAP-a i HCAP-a potrebno je pouzdano mikrobioloÅ”ko uzorkovanje s analizom kulture uz radioloÅ”ki nalaz novog ili progredirajuÄeg infiltrata na pluÄima. S obzirom na visok mortalitet, lijeÄenje suspektnog HAP-a, VAP-a i HCAP-a ne smije se odgaÄati te empirijski treba primijeniti antibiotik Å”irokog spektra. Ako su odsutni Äimbenici rizika od MDR-infekcije, empirijski se koristimo monoterapijom (beta-laktamima ili fluorokinolonima). Pri sumnji na infekciju MDR-uzroÄnikom izbor je empirijskog lijeÄenja kombinacija lijekova. āPrekrajanjemā poÄetno Å”irokog antibiotskog lijeÄenja prema nalazu testa osjetljivosti (deeskalacija) te kraÄom primjenom antibiotika smanjuje se rizik od nove multirezistencije, toksiÄnosti kombiniranog lijeÄenja i bolniÄke smrtnosti.Three types of hospital pneumonia are recognised by the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines: Hospital-acquired pneumonia (HAP), Ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP). Among all the hospital-acquired infections HAP is responsible for highest mortality rate. The stay in intensive care units increases the risk of pneumonia. Infection develops through microaspiration of bacteria from colonized oropharyngeal tract and may be polymicrobial and caused by multidrug resistant (MDR) pathogens. MDR is defined as resistance of bacteria to two or more antibiotics ordinarily used to treat this microorganism. MDR infection is expected in patients with certain risk factors: recent antibiotic use, recent or prolonged hospital stay, comorbidity, critical illness and exposure to local microbial flora. Besides clinical features (sudden onset fever, purulent tracheobronchial secretions, respiratory deterioration), the diagnosis of HAP, VAP and HCAP is made upon reliable microbiologic sampling and culture analysis in relation to the chest radiograph findings of new or progressive infiltrate. Considering a high mortality rate, the treatment of suspected HAP, VAP and HCAP should not be delayed and empiric broad spectrum antibiotic should be instituted. Empiric antibiotic monotherapy (beta-lactams or fluoroquinolones) is used in the absence of known risk factors for MDR infection. When MDR infection is suspected, empiric combination of drugs is the choice. Tailoring the broad spectrum therapy after susceptibility tests (de-escalation) and shortening the therapy duration reduces the risk of additional drug-resistance, toxicity of combination therapy and in-hospital mortality
Neinvazivna mehaniÄka ventilacija u akutnoj respiracijskoj insuficijenciji zbog COVID-19
Coronavirus disease 2019 (COVID-19) is presented with a wide range of symptoms,
from asymptomatic disease to severe and progressive interstitial pneumonia. As part of interstitial
pneumonia, respiratory failure is typically presented as hypoxia and is the most common cause of hospitalization.
When oxygen therapy fails, continuous positive airway pressure (CPAP) or noninvasive
mechanical ventilation (NIV) are used as respiratory support measures of first choice. Noninvasive respiratory
support (NIRS) is applied in order to save intensive care unit resources and to avoid complications
related to invasive mechanical ventilation. Emerging evidence has shown that the use of CPAP or NIV
in the management of acute hypoxemic respiratory failure in COVID-19 reduces the need for intubation
and mortality. The advantage of NIRS is the feasibility of its application on wards. NIV could be
administered via a face mask or helmet interface. Helmet adheres better than mask and therefore leakage
is reduced, a delivery of positive end-expiratory pressure is more accurate, and the risk of nosocomial
transmission of infections is lowered. Patients on NIRS must be carefully monitored so that further
respiratory deterioration is not overlooked and additional measures of care including timely intubation
and invasive mechanical ventilation could be performed if needed.Bolest uzrokovana novim koronavirusom 2019 (COVID-19) prezentira se Ŕirokim rasponom simptoma, od asimptomatske
bolesti do teÅ”ke i progresivne intersticijske upale pluÄa. Kao dio intersticijske pneumonije respiracijska insuficijencija
tipiÄno je obilježena hipoksijom i najÄeÅ”Äi je uzrok hospitalizacije. Kada terapija kisikom ne uspije, kontinuirani pozitivni
tlak u diÅ”nim putovima (CPAP) ili neinvazivna mehaniÄka ventilacija (NIV) mjere su respiracijske potpore prvog izbora.
Neinvazivna respiracijska potpora (NIRS) primjenjuje se kako bi se uÅ”tedjeli resursi jedinica intenzivnog lijeÄenja i izbjegle
komplikacije povezane s invazivnom mehaniÄkom ventilacijom. Uporaba CPAP-a ili NIV-a u lijeÄenju akutne hipoksemiÄne
respiracijske insuficijencije kod COVID-19 smanjuje potrebu za intubacijom i smrtnost. Prednost NIRS-a je da se može
provoditi na odjelima. NIV se može primijeniti preko maske ili kacige. Kaciga bolje prianja u odnosu na masku i stoga je
smanjen gubitak zraka, isporuka pozitivnog tlaka na kraju izdisaja je toÄnija, a rizik od nozokomijalnog prijenosa infekcija je
manji. Bolesnici na NIRS-u moraju se pažljivo nadzirati kako se ne bi previdjelo daljnje respiracijsko pogorŔanje i kako bi se
mogle provesti dodatne mjere skrbi ukljuÄujuÄi pravodobnu intubaciju i invazivnu mehaniÄku ventilaciju
Anemia, hypoalbuminemia, and elevated troponin levels as risk factors for respiratory failure in patients with severe exacerbations of chronic obstructive pulmonary disease requiring invasive mechanical ventilation
Aim To determine in-hospital and post-discharge mortality,
readmission rates, and predictors of invasive mechanical
ventilation (IMV) in patients treated at intensive care
unit (ICU) due to acute exacerbations of chronic obstructive
pulmonary disease (AECOPD).
Methods A retrospective observational cohort study included
all patients treated at a respiratory ICU for AECOPD
during one year. A total of 62 patients (41 men) with mean
age 68.4 Ā± 10.4 years were analyzed for outcomes including
in-hospital and post-discharge mortality, readmission
rates, and IMV. Patientsā demographic, hematologic, biochemical
data and arterial blood gas (ABG) values were recorded
on admission to hospital. Mean duration of followup
time was 2.4 years.
Results Of 62 patients, 7 (11.3%) died during incident hospitalization
and 21 (33.9%) died during the follow-up. The
overall 2.4-year mortality was 45.2%. Twenty nine (46.8%)
patients were readmitted due to AECOPD. The average
number of readmissions was 1.2. Multivariate analysis
showed that blood pH, bicarbonate levels, low albumin,
low serum chloride, and low hemoglobin were significant
predictors of IMV during incident hospitalization (P < 0.001
for the overall model fit).
Conclusion High in-hospital and post-discharge mortality
and high readmission rates in our patients treated due
to AECOPD at ICU indicate that these patients represent
a high risk group in need of close monitoring. Our results
suggested that anemia, hypoalbuminemia, and elevated
troponin levels were risk factors for the need of IMV in
severe AECOPD. Identification of such high-risk patients
could provide the opportunity for administration of an appropriate
and timely treatment
Value of Rapid Aetiological Diagnosis in Optimization of Antimicrobial Treatment in Bacterial Community Acquired Pneumonia
In 80 adult patients with community acquired pneumonia (CAP) conventional microbiological methods, polymerase
chain reaction (PCR) and serum C-reactive protein (CRP) levels were performed and the appropriateness of the empirical
antimicrobial treatment was evaluated according to bacterial pathogen detected. The aetiology was determined in 42
(52.5%) patients, with Streptococcus pneumoniae as the most common pathogen. PCR applied to bronchoalveolar lavage
(BAL) provided 2 and PCR on sputum samples 1 additional aetiological diagnosis of CAP. The mean CRP values in the
S. pneumoniae group were not significantly higher than in the group with other aetiological diagnoses (166.89 mg/L
vs.160.11 mg/L, p=0.457). In 23.8% (10/42) of patients with determined aetiology, the empirical antimicrobial treatment
was inappropriate. PCR tests need further investigation, particularly those for the atypical pathogens, as they are predominant
in inappropriately treated patients. Our results do not support the use of CRP as a rapid test to guide the
antimicrobial treatment in patients with CAP
NONINVASIVE VENTILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Neinvazivna mehaniÄka ventilacija (NIV) je ventilacija pozitivnim tlakom primijenjena preko neinvazivnih suÄelja. Smatra se standardnim naÄinom zbrinjavanja bolesnika hospitaliziranih zbog globalne respiracijske insufi cijencije u sklopu akutnog pogorÅ”anja kroniÄne opstruktivne pluÄne bolesti (KOPB). NIV poboljÅ”ava izmjenu plinova, smanjuje diÅ”ni rad i posljediÄno omoguÄava oporavak diÅ”ne muskulature. Dokazano je da NIV može reducirati potrebu za intubacijom, morbiditet i mortalitet pacijenata s teÅ”kim pogorÅ”anjem KOPB-a. NIV skraÄuje vrijeme lijeÄenja u jedinicama intenzivne skrbi i ukupno trajanje bolniÄkog lijeÄenja. Može se koristiti u svrhu olakÅ”avanja odvajanja bolesnika od invazivne mehaniÄke ventilacije i prevenciji razvoja respiracijske insufi cijencije nakon ekstubacije. U bolesnika s teÅ”kom respiracijskom acidozom i poremeÄajem svijesti postoji visok rizik neuspjeha lijeÄenja NIV-om. U tih bolesnika lijeÄenje NIV-om treba provoditi uz intenzivni nadzor i u uvjetima koji omoguÄavaju brzu endotrahejsku intubaciju u sluÄaju potrebe. Kontroverzni su podatci o koristi dugotrajne primjene NIV-a u stabilnom KOPB-u. U odnosu na standardno lijeÄenje, primjena NIV-a visokog intenziteta poboljÅ”ava ishode ovih bolesnika. NIV visokog intenziteta poboljÅ”ava izmjenu diÅ”nih plinova, pluÄnu funkciju, kvalitetu života vezanu uz zdravlje, podnoÅ”enje fi ziÄkog napora i preživljenje. Dodatak NIV-a u stabilnoj fazi bolesti programu respiratorne rehabilitacije poboljÅ”ava rezultate respiratorne rehabilitacije. S obzirom da NIV pruža niz koristi bolesnicima s KOPB-om svaki bi lijeÄnik koji je
ukljuÄen u lijeÄenje ovih bolesnika trebao vladati ovom tehnikom.Noninvasive ventilation (NIV) refers to positive pressure ventilation that is delivered through a noninvasive interface. It is considered as a standard treatment for patients admitted to hospital with hypercapnic respiratory failure secondary to acute exacerbation of chronic obstructive pulmonary disease (COPD). NIV improves gas exchange and reduces respiratory muscle work, consequently allowing respiratory muscle recovery. The available evidence establishes that NIV might reduce intubation, morbidity and mortality rates in patients with severe COPD exacerbations. NIV shortens intensive care unit and total hospital lengths of stay. It can be used to facilitate the process of weaning from mechanical ventilation and prevent development of post-extubation respiratory failure. Patients with severe respiratory acidosis or with altered levels of consciousness due to carbon dioxide retention are at a high risk of NIV failure. In these patients, a NIV trial should be attempted in closely monitored clinical conditions where prompt endotracheal intubation may be performed. The benefi ts of long-term NIV management of stable COPD are still controversial. However, implementation of high-intensity NIV has been shown to improve outcomes in this patient group. High-intensity NIV improves gas exchange, lung function, health-related quality of life, exercise tolerance and survival compared to standard care alone. In stable severe COPD, the addition of NIV to a pulmonary rehabilitation program improves outcomes as compared to pulmonary rehabilitation alone. Since NIV provides signifi cant benefi ts in COPD, every physician who is involved in the treatment of these patients should be familiar with this technique
Influence of the initial continuous positive airway pressure treatment on REM sleep in patients with sleep apnea syndromes
Na temelju dosadaÅ”njih istraživanja postavili smo hipotezu da prvotna primjena kontinuiranoga pozitivnoga tlaka zraka u diÅ”nim putevima (CPAP) dovodi do normalizacije respiracijskih parametara i oporavka REM-a u bolesnika s apnejom u spavanju. Centralna apneja u spavanju (CSA) do sada nije istraživana u tome smislu. Pretpostavili smo veÄi uÄinak CPAP-a na REM u bolesnika s opstruktivnom apnejom u spavanju (OSA), osobito u podskupini OSA-e s predominacijom mjeÅ”ovitih epizoda, a manji u bolesnika s CSA-om. Retrospektivno smo analizirali demografske i komorbiditetne podatke te usporedili polisomnografske izvjeÅ”taje prije i nakon CPAP-a u odraslih bolesnika s umjerenom i teÅ”kom apnejom u spavanju evaluiranih u naÅ”em laboratoriju. U studiju je ukljuÄeno dvjestoÅ”ezdeset bolesnika (183 s predominacijom opstruktivnih epizoda apneje, 61 s predominacijom
mjeÅ”ovitih epizoda, 16 s predominacijom centralnih epizoda). Hipertenzija je bila jedina znaÄajna razlika u karakteristikama meÄu trima skupinama. StatistiÄki znaÄajan oporavak REM-a nakon CPAP-a ustanovljen je u svih bolesnika s apnejom u spavanju, osobito u opstruktivnoj i mjeÅ”ovitoj skupini (bez znaÄajne meÄusobne razlike), no nedovoljan u centralnoj ā usprkos uspjeÅ”noj korekciji apneja-hipopneja indeksa (AHI) u sve tri skupine. Predloženi su drugi Äimbenici odgovorni za nedovoljan oporavak REM-a u CSA-e nakon CPAP-a. ZakljuÄujemo da je poveÄanje REM-a u apneje u spavanju nakon prvotne primjene CPAP-a snažno povezano s korekcijom AHI-ja.Regarding former studies, we hypothesized that initial continuous positive airway pressure (CPAP) treatment is leading to the respiratory normalization and rapid eye movement (REM) rebound in patients with sleep apnea. Central sleep apnea (CSA) was not evaluated in this regard so far. We anticipated better effect of CPAP on REM in obstructive sleep apnea (OSA) patients, especially in OSA with mixed apnea-predominant subgroup, and lesser in CSA patients. We retrospectively analyzed data regarding demographics and comorbidities and compared polysomnography reports before and after initial CPAP of moderate and severe sleep apnea patients evaluated in our sleep lab. Two hundred and sixty patients (183 obstructive apnea-predominant, 61 mixed apnea-predominant, 16 central apnea-predominant) were included in the study. Hypertension was the only significantly different characteristic among three groups. Statistically significant REM rebound after CPAP was found in all sleep apnea patients, especially in obstructive and mixed apnea groups (without the difference between the groups), but insignificant in central apnea group ā regardless of successful apneahypopnea index (AHI) reduction in all three groups. Other factors responsible for lack of REM rebound in CSA after CPAP were proposed. We conclude that REM rebound in sleep apnea following first CPAP usage strongly correlated with AHI reduction
Influence of the initial continuous positive airway pressure treatment on REM sleep in patients with sleep apnea syndromes
Na temelju dosadaÅ”njih istraživanja postavili smo hipotezu da prvotna primjena kontinuiranoga pozitivnoga tlaka zraka u diÅ”nim putevima (CPAP) dovodi do normalizacije respiracijskih parametara i oporavka REM-a u bolesnika s apnejom u spavanju. Centralna apneja u spavanju (CSA) do sada nije istraživana u tome smislu. Pretpostavili smo veÄi uÄinak CPAP-a na REM u bolesnika s opstruktivnom apnejom u spavanju (OSA), osobito u podskupini OSA-e s predominacijom mjeÅ”ovitih epizoda, a manji u bolesnika s CSA-om. Retrospektivno smo analizirali demografske i komorbiditetne podatke te usporedili polisomnografske izvjeÅ”taje prije i nakon CPAP-a u odraslih bolesnika s umjerenom i teÅ”kom apnejom u spavanju evaluiranih u naÅ”em laboratoriju. U studiju je ukljuÄeno dvjestoÅ”ezdeset bolesnika (183 s predominacijom opstruktivnih epizoda apneje, 61 s predominacijom
mjeÅ”ovitih epizoda, 16 s predominacijom centralnih epizoda). Hipertenzija je bila jedina znaÄajna razlika u karakteristikama meÄu trima skupinama. StatistiÄki znaÄajan oporavak REM-a nakon CPAP-a ustanovljen je u svih bolesnika s apnejom u spavanju, osobito u opstruktivnoj i mjeÅ”ovitoj skupini (bez znaÄajne meÄusobne razlike), no nedovoljan u centralnoj ā usprkos uspjeÅ”noj korekciji apneja-hipopneja indeksa (AHI) u sve tri skupine. Predloženi su drugi Äimbenici odgovorni za nedovoljan oporavak REM-a u CSA-e nakon CPAP-a. ZakljuÄujemo da je poveÄanje REM-a u apneje u spavanju nakon prvotne primjene CPAP-a snažno povezano s korekcijom AHI-ja.Regarding former studies, we hypothesized that initial continuous positive airway pressure (CPAP) treatment is leading to the respiratory normalization and rapid eye movement (REM) rebound in patients with sleep apnea. Central sleep apnea (CSA) was not evaluated in this regard so far. We anticipated better effect of CPAP on REM in obstructive sleep apnea (OSA) patients, especially in OSA with mixed apnea-predominant subgroup, and lesser in CSA patients. We retrospectively analyzed data regarding demographics and comorbidities and compared polysomnography reports before and after initial CPAP of moderate and severe sleep apnea patients evaluated in our sleep lab. Two hundred and sixty patients (183 obstructive apnea-predominant, 61 mixed apnea-predominant, 16 central apnea-predominant) were included in the study. Hypertension was the only significantly different characteristic among three groups. Statistically significant REM rebound after CPAP was found in all sleep apnea patients, especially in obstructive and mixed apnea groups (without the difference between the groups), but insignificant in central apnea group ā regardless of successful apneahypopnea index (AHI) reduction in all three groups. Other factors responsible for lack of REM rebound in CSA after CPAP were proposed. We conclude that REM rebound in sleep apnea following first CPAP usage strongly correlated with AHI reduction
Influence of the initial continuous positive airway pressure treatment on REM sleep in patients with sleep apnea syndromes
Na temelju dosadaÅ”njih istraživanja postavili smo hipotezu da prvotna primjena kontinuiranoga pozitivnoga tlaka zraka u diÅ”nim putevima (CPAP) dovodi do normalizacije respiracijskih parametara i oporavka REM-a u bolesnika s apnejom u spavanju. Centralna apneja u spavanju (CSA) do sada nije istraživana u tome smislu. Pretpostavili smo veÄi uÄinak CPAP-a na REM u bolesnika s opstruktivnom apnejom u spavanju (OSA), osobito u podskupini OSA-e s predominacijom mjeÅ”ovitih epizoda, a manji u bolesnika s CSA-om. Retrospektivno smo analizirali demografske i komorbiditetne podatke te usporedili polisomnografske izvjeÅ”taje prije i nakon CPAP-a u odraslih bolesnika s umjerenom i teÅ”kom apnejom u spavanju evaluiranih u naÅ”em laboratoriju. U studiju je ukljuÄeno dvjestoÅ”ezdeset bolesnika (183 s predominacijom opstruktivnih epizoda apneje, 61 s predominacijom
mjeÅ”ovitih epizoda, 16 s predominacijom centralnih epizoda). Hipertenzija je bila jedina znaÄajna razlika u karakteristikama meÄu trima skupinama. StatistiÄki znaÄajan oporavak REM-a nakon CPAP-a ustanovljen je u svih bolesnika s apnejom u spavanju, osobito u opstruktivnoj i mjeÅ”ovitoj skupini (bez znaÄajne meÄusobne razlike), no nedovoljan u centralnoj ā usprkos uspjeÅ”noj korekciji apneja-hipopneja indeksa (AHI) u sve tri skupine. Predloženi su drugi Äimbenici odgovorni za nedovoljan oporavak REM-a u CSA-e nakon CPAP-a. ZakljuÄujemo da je poveÄanje REM-a u apneje u spavanju nakon prvotne primjene CPAP-a snažno povezano s korekcijom AHI-ja.Regarding former studies, we hypothesized that initial continuous positive airway pressure (CPAP) treatment is leading to the respiratory normalization and rapid eye movement (REM) rebound in patients with sleep apnea. Central sleep apnea (CSA) was not evaluated in this regard so far. We anticipated better effect of CPAP on REM in obstructive sleep apnea (OSA) patients, especially in OSA with mixed apnea-predominant subgroup, and lesser in CSA patients. We retrospectively analyzed data regarding demographics and comorbidities and compared polysomnography reports before and after initial CPAP of moderate and severe sleep apnea patients evaluated in our sleep lab. Two hundred and sixty patients (183 obstructive apnea-predominant, 61 mixed apnea-predominant, 16 central apnea-predominant) were included in the study. Hypertension was the only significantly different characteristic among three groups. Statistically significant REM rebound after CPAP was found in all sleep apnea patients, especially in obstructive and mixed apnea groups (without the difference between the groups), but insignificant in central apnea group ā regardless of successful apneahypopnea index (AHI) reduction in all three groups. Other factors responsible for lack of REM rebound in CSA after CPAP were proposed. We conclude that REM rebound in sleep apnea following first CPAP usage strongly correlated with AHI reduction